Bahrami F, van Hezik C, Bergman A, Brandt I
Department of Environmental Toxicology, Uppsala University, Norbyvägen 18A, S-752 36, Uppsala, Sweden.
Chem Biol Interact. 2000 Oct 16;128(2):97-113. doi: 10.1016/s0009-2797(00)00187-3.
Previously we reported that methylsulphonyl-2,6-dichlorobenzene, 2, 6-(diCl-MeSO(2)-B), was irreversibly bound to the olfactory mucosa of mice and induced necrosis of the Bowman's glands with subsequent neuroepithelial degeneration and detachment. In this study, autoradiography and histopathology were used to determine tissue-localization and toxicity of 2,6-(diCl-MeSO(2)-B) in the olfactory mucosa of control mice and animals pretreated with cytochrome P450 (CYP) and glutathione (GSH) modulators. The Bowman's glands of the olfactory mucosa were the major target sites of non-extractable binding of 2,6-(diCl-(14)C-MeSO(2)-B), whereas the olfactory neuroepithelium and nerve bundles showed only background levels of silver grains. Metyrapone pretreatment slightly decreased binding in the Bowman's glands and markedly decreased toxicity in the olfactory mucosa after 2,6-(diCl-MeSO(2)-B) administration. These results support that a CYP-mediated activation of 2, 6-(diCl-MeSO(2)-B) takes place in the Bowman's glands giving rise to toxic reactive intermediates. In mice pretreated with the GSH-depleting agent phorone, a marked increase of irreversible binding of 2,6-(diCl-(14)C-MeSO(2)-B) in the Bowman's glands was observed. Tape-section autoradiograms also revealed a significant increase of uptake of radioactivity in the olfactory bulb. As determined by histopathology, GSH-depletion increased both the extent and severity of the lesion in the mucosa. These results imply that 2,6-(diCl-MeSO(2)-B)-reactive intermediates are conjugated with GSH. The amount of irreversible binding and toxicity in the olfactory mucosa seems to be associated with the level of 2, 6-(diCl-MeSO(2)-B)-reactive intermediates.
此前我们报道过,甲基磺酰基 - 2,6 - 二氯苯(2,6 - (diCl - MeSO₂ - B))会不可逆地结合到小鼠的嗅觉黏膜上,并导致鲍曼腺坏死,随后出现神经上皮变性和脱落。在本研究中,利用放射自显影术和组织病理学来确定2,6 - (diCl - MeSO₂ - B)在对照小鼠以及用细胞色素P450(CYP)和谷胱甘肽(GSH)调节剂预处理的动物的嗅觉黏膜中的组织定位和毒性。嗅觉黏膜的鲍曼腺是2,6 - (diCl - ¹⁴C - MeSO₂ - B)不可提取结合的主要靶位点,而嗅觉神经上皮和神经束仅显示背景水平的银粒。美替拉酮预处理略微降低了鲍曼腺中的结合,并在给予2,6 - (diCl - MeSO₂ - B)后显著降低了嗅觉黏膜中的毒性。这些结果支持在鲍曼腺中发生了CYP介导的2,6 - (diCl - MeSO₂ - B)活化,产生了有毒的反应性中间体。在用谷胱甘肽消耗剂佛尔酮预处理的小鼠中,观察到鲍曼腺中2,6 - (diCl - ¹⁴C - MeSO₂ - B)的不可逆结合显著增加。胶带切片放射自显影图还显示嗅球中放射性摄取显著增加。通过组织病理学确定,谷胱甘肽耗竭增加了黏膜病变的范围和严重程度。这些结果表明2,6 - (diCl - MeSO₂ - B)反应性中间体与谷胱甘肽结合。嗅觉黏膜中不可逆结合和毒性的量似乎与2,6 - (diCl - MeSO₂ - B)反应性中间体的水平相关。